Company intelligence / Profile preview

Lachlogen

Charlottesville, Virginia, USA

Ownership: Private
Development stage: Other

Overview

Lacregen is a clinical-stage biotechnology company focused on developing novel peptide therapeutics for ophthalmology, specifically targeting dry eye disease and Sjögren's syndrome. The company's lead candidate, Lacripep, is a topical synthetic peptide fragment derived from the natural human tear protein lacritin. This therapeutic approach aims to restore the natural tear film by promoting basal tear secretion and corneal epithelial healing. Lacregen's technology is based on the discovery of lacritin's role in ocular surface health and seeks to provide a disease-modifying alternative to current palliative treatments.

Therapeutic areas: ImmunologyOphthalmology
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

La Chlogen

Unknown

Beyond the preview

Go deeper on Lachlogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lachlogen.

Explore the full profile